Enhanced Protective Immunogenicity of Homodimeric Borrelia burgdorferi Outer Surface Protein C.

Q2 Biochemistry, Genetics and Molecular Biology
Clinical and Vaccine Immunology Pub Date : 2017-01-05 Print Date: 2017-01-01 DOI:10.1128/CVI.00306-16
Diane G Edmondson, Sabitha Prabhakaran, Steven J Norris, Amy J Ullmann, Joe Piesman, Marc Dolan, Christian Probst, Christiane Radzimski, Winfried Stöcker, Lars Komorowski
{"title":"Enhanced Protective Immunogenicity of Homodimeric Borrelia burgdorferi Outer Surface Protein C.","authors":"Diane G Edmondson, Sabitha Prabhakaran, Steven J Norris, Amy J Ullmann, Joe Piesman, Marc Dolan, Christian Probst, Christiane Radzimski, Winfried Stöcker, Lars Komorowski","doi":"10.1128/CVI.00306-16","DOIUrl":null,"url":null,"abstract":"<p><p>Lyme borreliosis is caused by tick-transmitted spirochetes of the Borrelia burgdorferi sensu lato group and is the most common vector-borne disease in the United States and Europe. Outer surface protein C (OspC) is a 23-kDa outer surface lipoprotein expressed during spirochete transmission from the tick to the vertebrate host. In a previous study, we found that immunization with a recombinant disulfide-bridged dimeric form of OspC (D-OspC) stimulates increased antibody responses relative to immunization with commonly employed monomeric OspC. Here, we report that mice immunized with dimeric OspC proteins also exhibited enhanced protection against infection with the cognate B. burgdorferi strain. Mice were protected by four immunizations containing as little as 100 ng of dimeric OspC, suggesting that this form of the protein can induce protective immunity within a dose range reasonable for a human or veterinary vaccine. In contrast, monomeric OspC was only partially protective at much higher doses. IgG subclass analysis revealed that D-OspC-immunized animals mainly possessed anti-OspC-IgG1. In contrast, infected animals develop anti-OspC restricted to the IgG3 isotype. A subset of antibodies generated by dimeric OspC immunization did not recognize the monomeric variant, indicating that unique epitopes exist on the dimeric form. Moreover, monoclonal antibodies that recognized only dimeric OspC protected mice from B. burgdorferi challenge, whereas another monoclonal that recognized both immunogens was not protective. These studies suggest that this dimeric OspC presents distinctive epitopes that generate antibodies protective against B. burgdorferi infection and could be a useful vaccine component.</p>","PeriodicalId":10271,"journal":{"name":"Clinical and Vaccine Immunology","volume":"19 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2017-01-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5216437/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical and Vaccine Immunology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1128/CVI.00306-16","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2017/1/1 0:00:00","PubModel":"Print","JCR":"Q2","JCRName":"Biochemistry, Genetics and Molecular Biology","Score":null,"Total":0}
引用次数: 0

Abstract

Lyme borreliosis is caused by tick-transmitted spirochetes of the Borrelia burgdorferi sensu lato group and is the most common vector-borne disease in the United States and Europe. Outer surface protein C (OspC) is a 23-kDa outer surface lipoprotein expressed during spirochete transmission from the tick to the vertebrate host. In a previous study, we found that immunization with a recombinant disulfide-bridged dimeric form of OspC (D-OspC) stimulates increased antibody responses relative to immunization with commonly employed monomeric OspC. Here, we report that mice immunized with dimeric OspC proteins also exhibited enhanced protection against infection with the cognate B. burgdorferi strain. Mice were protected by four immunizations containing as little as 100 ng of dimeric OspC, suggesting that this form of the protein can induce protective immunity within a dose range reasonable for a human or veterinary vaccine. In contrast, monomeric OspC was only partially protective at much higher doses. IgG subclass analysis revealed that D-OspC-immunized animals mainly possessed anti-OspC-IgG1. In contrast, infected animals develop anti-OspC restricted to the IgG3 isotype. A subset of antibodies generated by dimeric OspC immunization did not recognize the monomeric variant, indicating that unique epitopes exist on the dimeric form. Moreover, monoclonal antibodies that recognized only dimeric OspC protected mice from B. burgdorferi challenge, whereas another monoclonal that recognized both immunogens was not protective. These studies suggest that this dimeric OspC presents distinctive epitopes that generate antibodies protective against B. burgdorferi infection and could be a useful vaccine component.

同源二聚体伯氏疏螺旋体外表面蛋白C的保护性免疫原性增强。
莱姆病是由蜱传播的伯氏疏螺旋体引起的,是美国和欧洲最常见的媒介传播疾病。外表面蛋白C (OspC)是一种23 kda的外表面脂蛋白,在蜱虫向脊椎动物宿主的螺旋体传播过程中表达。在之前的一项研究中,我们发现用重组二硫桥接二聚体形式的OspC (D-OspC)进行免疫,相对于用通常使用的单体OspC进行免疫,可以刺激更高的抗体反应。在这里,我们报道用二聚体OspC蛋白免疫的小鼠也表现出对同源伯氏疏螺旋体菌株感染的增强保护。小鼠受到四种免疫接种的保护,这些免疫接种只含有100 ng二聚体OspC,这表明这种形式的蛋白质可以在人或兽用疫苗的合理剂量范围内诱导保护性免疫。相比之下,单体OspC在高得多的剂量下只有部分保护作用。IgG亚类分析显示,d - ospc免疫动物主要具有抗ospc - igg1。相比之下,受感染的动物产生的抗ospc仅限于IgG3同型。二聚体OspC免疫产生的一部分抗体不能识别单体变异,这表明二聚体形式存在独特的表位。此外,仅识别二聚体OspC的单克隆抗体可以保护小鼠免受伯氏疏螺旋体的攻击,而识别两种免疫原的单克隆抗体则没有保护作用。这些研究表明,这种二聚体OspC具有独特的表位,可产生抗伯氏疏螺旋体感染的抗体,可能是一种有用的疫苗成分。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Clinical and Vaccine Immunology
Clinical and Vaccine Immunology 医学-传染病学
CiteScore
2.88
自引率
0.00%
发文量
0
审稿时长
1.5 months
期刊介绍: Cessation. First launched as Clinical and Diagnostic Laboratory Immunology (CDLI) in 1994, CVI published articles that enhanced the understanding of the immune response in health and disease and after vaccination by showcasing discoveries in clinical, laboratory, and vaccine immunology. CVI was committed to advancing all aspects of vaccine research and immunization, including discovery of new vaccine antigens and vaccine design, development and evaluation of vaccines in animal models and in humans, characterization of immune responses and mechanisms of vaccine action, controlled challenge studies to assess vaccine efficacy, study of vaccine vectors, adjuvants, and immunomodulators, immune correlates of protection, and clinical trials.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信
小红书